What happened with PLSE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pulse Biosciences is still largely a research and clinical-development business. Its current commercial activity centers on the Vybrance Percutaneous Electrode System, which physicians use to treat benign thyroid nodules. Limited-release sales of this device account for its recent product revenue. The company markets it mainly to ear, nose and throat specialists, endocrine surgeons and interventional radiologists.
Vybrance and the company’s products under development rely on the same Nano-pulse Stimulation (NPS) platform. Pulse Biosciences is also developing the nPulse Cardiac Catheter and nPulse Cardiac Surgery Clamp for treating atrial fibrillation, an irregular heart rhythm. Clinical experience in both thyroid and cardiac applications remains limited. Wider sales depend on physicians learning and adopting the devices, and on insurers covering the treatments at adequate payment levels. New devices and new intended uses generally need regulatory clearance or approval before they can be marketed.
Product sales do not yet sustain the business. Pulse Biosciences has funded operations mainly through share issuances and debt and needs further capital for development and commercialization. Majority shareholder and Co-Chairman Robert Duggan has been a significant financial backer, but further support from him is not assured.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
AtriCure already sells medical centers devices for surgically treating atrial fibrillation, putting an established supplier against Pulse Biosciences’ cardiac ablation development programs. Its sales of disposable ablation devices and probes are the relevant business to watch, rather than its post-operative pain products.
Boston Scientific’s FARAPULSE competes in atrial-fibrillation procedures with the cardiac ablation technology Pulse Biosciences is still developing. Watch FARAPULSE’s progress: Pulse warns that rapid advances in competing pulsed-field ablation systems could leave its technology obsolete or uncompetitive.
Merit Medical sells systems that use heat from radiofrequency energy to treat benign thyroid nodules, competing with Pulse Biosciences’ nPulse alternative. Its thyroid-ablation offering matters because established thermal treatments already benefit from physician familiarity, long-term clinical evidence and reimbursement pathways.
Medtronic’s Pulse Select competes with Pulse Biosciences’ developing pulsed-field ablation technology for atrial-fibrillation treatment. Further improvements to Pulse Select matter for Pulse’s competitive position: Pulse says rival systems have already reshaped treatment inside the heart within a few years.
Johnson & Johnson’s Biosense Webster competes with Pulse Biosciences in cardiac ablation for atrial-fibrillation treatment. Pulse identifies established competitors’ deeper healthcare-provider relationships and stronger sales and support capabilities as advantages its developing technology must face.
Abbott sells cardiac ablation technologies that compete with Pulse Biosciences’ developing atrial-fibrillation treatments. For Pulse, the challenge extends beyond the technology: it says established rivals have greater research resources and more experience in trials, regulatory approvals and manufacturing.
Boston Scientific Corp. earningsBSX
Boston Scientific’s report will show how FARAPULSE’s progress shapes the competition facing Pulse Biosciences’ cardiac ablation technology in development.
Watch Boston Scientific’s cardiac ablation business and any reported progress for FARAPULSE. Continued growth would indicate that hospitals and physicians are still adopting established pulsed-field ablation systems, making it harder for Pulse Biosciences’ technology in development to win use. Weaker progress would offer less evidence of momentum for those rivals, but would not show that demand for Pulse’s technology is rising. The question is whether established systems are still raising the bar for clinical adoption.
Fed Interest Rate Decision
The Fed’s rate decision signals the direction of borrowing costs across the economy, while higher rates can also lift the interest Pulse Biosciences earns on its cash to help fund its research and commercialization.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates may increase Pulse Biosciences’ interest income on cash, helping fund its work, but can also make any new borrowing more costly.
If it comes in below expectations
Lower rates may reduce Pulse Biosciences’ interest income on cash, leaving less income to support its work, but can make any new borrowing cheaper.
Merit Medical Systems Inc earningsMMSI
Merit Medical’s report can show how its thyroid-ablation business is progressing and how much established-treatment competition Pulse Biosciences’ NPS alternative faces.
Watch the performance of Merit Medical’s thyroid-ablation business. Growth would indicate continued use of radiofrequency heat treatment, an established option with physician familiarity, clinical evidence and reimbursement pathways; Pulse Biosciences’ NPS alternative would have to displace a firmer incumbent choice. Slower progress would show less momentum for that competing treatment, not prove that NPS is gaining use. The conclusion is whether established heat-based treatment is still strengthening its place in benign thyroid nodules.
Pulse Biosciences, Inc earningsThis company
Pulse Biosciences’ report will show whether early Vybrance sales are growing enough to begin supporting the company’s research and commercialization spending.
Read Vybrance product revenue alongside the cost of product revenue and cash used in operations. Growing sales without costs and cash use rising faster would show that the newly launched product is gaining commercial traction. Stalled or very limited sales while operating cash use remains heavy would show that sales are not yet supporting the company’s spending and financing remains essential.
